332 related articles for article (PubMed ID: 28611343)
1. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.
Al Ashgar H; Peedikayil MC; Al Quaiz M; Al Sohaibani F; Al Fadda A; Khan MQ; Thoralsson E; Al Thawadi S; Al Jedai A; Al Kahtani K
Saudi J Gastroenterol; 2017; 23(3):190-198. PubMed ID: 28611343
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
3. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
4. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
6. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
7. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.
Tatsukawa Y; Tsuge M; Kawakami Y; Hiyama Y; Murakami E; Kurihara M; Nomura M; Tsushima K; Uchida T; Nakahara T; Miki D; Kawaoka T; Abe-Chayama H; Imamura M; Aikata H; Ochi H; Hayes CN; Kawakami H; Chayama K
Antivir Ther; 2018; 23(8):639-646. PubMed ID: 29856363
[TBL] [Abstract][Full Text] [Related]
8. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
9. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
Marcellin P; Ahn SH; Chuang WL; Hui AJ; Tabak F; Mehta R; Petersen J; Lee CM; Ma X; Caruntu FA; Tak WY; Elkhashab M; Lin L; Wu G; Martins EB; Charuworn P; Yee LJ; Lim SG; Foster GR; Fung S; Morano L; Samuel D; Agarwal K; Idilman R; Strasser SI; Buti M; Gaeta GB; Papatheodoridis G; Flisiak R; Chan HL
Aliment Pharmacol Ther; 2016 Nov; 44(9):957-966. PubMed ID: 27629859
[TBL] [Abstract][Full Text] [Related]
10. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
Marcellin P; Ahn SH; Ma X; Caruntu FA; Tak WY; Elkashab M; Chuang WL; Lim SG; Tabak F; Mehta R; Petersen J; Foster GR; Lou L; Martins EB; Dinh P; Lin L; Corsa A; Charuworn P; Subramanian GM; Reiser H; Reesink HW; Fung S; Strasser SI; Trinh H; Buti M; Gaeta GB; Hui AJ; Papatheodoridis G; Flisiak R; Chan HL;
Gastroenterology; 2016 Jan; 150(1):134-144.e10. PubMed ID: 26453773
[TBL] [Abstract][Full Text] [Related]
11. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B.
Kittner JM; Sprinzl MF; Grambihler A; Weinmann A; Schattenberg JM; Galle PR; Schuchmann M
J Clin Virol; 2012 May; 54(1):93-5. PubMed ID: 22365367
[TBL] [Abstract][Full Text] [Related]
12. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
[TBL] [Abstract][Full Text] [Related]
13. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
14. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.
Matsumoto A; Nishiguchi S; Enomoto H; Tanaka Y; Shinkai N; Okuse C; Kang JH; Matsui T; Miyase S; Yatsuhashi H; Nagaoka S; Kanda T; Enomoto M; Yamada R; Hiramatsu N; Saito S; Takaguchi K; Ito K; Masaki T; Morihara D; Tsuge M; Chayama K; Ikeda F; Kagawa T; Kondo Y; Murata K; Tanaka E
J Gastroenterol; 2020 Oct; 55(10):977-989. PubMed ID: 32666202
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
Ahn SH; Marcellin P; Ma X; Caruntu FA; Tak WY; Elkhashab M; Chuang WL; Tabak F; Mehta R; Petersen J; Guyer W; Jump B; Chan A; Subramanian M; Crans G; Fung S; Buti M; Gaeta GB; Hui AJ; Papatheodoridis G; Flisiak R; Chan HLY
Dig Dis Sci; 2018 Dec; 63(12):3487-3497. PubMed ID: 30136045
[TBL] [Abstract][Full Text] [Related]
17. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
18. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
[TBL] [Abstract][Full Text] [Related]
19. HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype.
Stanzione M; Stornaiuolo G; Rizzo V; Pontarelli A; Gaeta GB
Infez Med; 2016 Jun; 24(2):144-6. PubMed ID: 27367326
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
